CN114224935A - Cold compress spray for relieving gout and preparation method thereof - Google Patents

Cold compress spray for relieving gout and preparation method thereof Download PDF

Info

Publication number
CN114224935A
CN114224935A CN202111664767.0A CN202111664767A CN114224935A CN 114224935 A CN114224935 A CN 114224935A CN 202111664767 A CN202111664767 A CN 202111664767A CN 114224935 A CN114224935 A CN 114224935A
Authority
CN
China
Prior art keywords
spray
cold compress
water
relieving gout
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111664767.0A
Other languages
Chinese (zh)
Inventor
何新桥
何山
何小珊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changde Jizhi Biotechnology Co ltd
Original Assignee
Changde Jizhi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changde Jizhi Biotechnology Co ltd filed Critical Changde Jizhi Biotechnology Co ltd
Priority to CN202111664767.0A priority Critical patent/CN114224935A/en
Publication of CN114224935A publication Critical patent/CN114224935A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/46Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a cold compress spray for relieving gout and a preparation method thereof; the cold compress spray for relieving gout comprises: the cold compress spray is an external medicine, adverse reaction and toxic and side effects are remarkably reduced, and the cold compress spray has good permeability, can immediately decompose the tophus after being quickly kneaded and absorbed by hands, promotes blood circulation, quickly relieves pain, has obvious treatment effect, remarkably improves the medication compliance of patients with gouty arthritis, and improves the life quality of the patients.

Description

Cold compress spray for relieving gout and preparation method thereof
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a cold compress spray for relieving gout and a preparation method thereof.
Background
Gout is directly related to hyperuricemia caused by purine metabolic disorder and/or reduction of uric acid excretion, and belongs to the category of metabolic rheumatism. Gout can be complicated with kidney disease, and severe cases can cause joint destruction and renal function damage, often accompanied with hyperlipidemia, hypertension, diabetes, arteriosclerosis, coronary heart disease, etc. Hyperuricemia is the basis for the development of gout.
Gout belongs to the categories of arthralgia syndrome, gout, historical segment and the like in traditional Chinese medicine, and refers to symptoms of arthralgia, myalgia, numbness, heaviness and unsmooth flexion and extension caused by exogenous pathogenic factors blocking channels and collaterals, stagnation of qi and blood and deficiency of liver and kidney. Gout patients often develop tophi. Seen subcutaneously around the pinna, around the joints, tendons, soft tissues, etc. of the patient. Tophus formed on various parts of the body, especially four limbs, not only seriously affects the appearance of the limbs, but also leads to joint deformity, dysfunction, nerve compression, skin ulceration and prolonged unhealed sinus, and needs to be treated by operation.
At present, colchicine is used as a treatment medicament for gouty arthritis, and Baotan or indomethacin can be selected. The continuous rise of serum uric acid can also be treated by using the carbendazim, and the medicine plays a role in treating the reabsorption of urate by inhibiting renal tubules and is one of effective treatment medicines. If kidney disease is present, allopurines are often the treatment of choice. In the acute stage, steroid injection into joints, joint immobilization and cold compress of local parts can obviously relieve symptoms. However, although the western medicines can rapidly relieve symptoms, the recurrence rate is high, and the disease can rebound after the medicine is stopped, the western medicines must be taken for a long time without interruption, so that the western medicines bring a large economic burden to patients, and the western medicines have large toxic and side effects on the kidney after long-term administration. Therefore, the development of a spray for effectively treating gouty arthritis is a problem which needs to be solved at present.
Disclosure of Invention
The invention aims to provide a cold compress spray for relieving gout, which has the advantages of quick response, short treatment course, low toxic and side effects, simple preparation process and convenient use.
Specifically, the present invention provides:
a cold compress spray for relieving gout comprises: alkaline ionized water, sodium bicarbonate, L-carnitine, eucommia bark water extract, green olive juice and monosodium glutamate.
The cold compress spray for relieving gout comprises the following components in parts by weight:
Figure BDA0003451478910000021
the pH value of the alkaline ionized water is 10.0-10.9.
A preparation method of a cold compress spray for relieving gout comprises the following steps:
step 1, adding baking soda into alkaline ionized water, and after uniformly stirring, enabling the pH value to reach 12-13;
step 2, adding L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding the green olive juice of the eucommia bark water extract into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
The alkaline ionized water of the present invention is water that is directly collected or produced by an alkaline ion water treatment apparatus (also referred to as an alkaline ionizer) and exhibits alkalinity, and is also referred to as electrolyzed water. The alkaline ionized water is purchased from the Kyoto Shanghai city, and the brand is imported table salt ocean alkaline ionized water.
Preparing a eucommia bark water extract: pulverizing cortex Eucommiae, sieving with 60 mesh sieve, weighing 40g powder, boiling in 1000mL sterile distilled water for 4h, filtering with 300 mesh sieve, collecting filtrate, concentrating in water bath, evaporating to obtain dry liquid, and adding distilled water to obtain cortex Eucommiae water extract with concentration of 3 g/L.
Preparation of green olive juice: putting the cleaned green olive into boiling water, adding 0.1% citric acid solution, scalding for 5min, taking out, washing in flowing water to remove surface wax, softening pulp tissue, and protecting color; extracting the pitted olive pulp in a material-water ratio of 1:5(g/mL) for 2h at 50 ℃ and 400r/min in a temperature-controlled stirrer; filtering the extracted olive juice with gauze to obtain clear and transparent green olive juice.
The baking soda and the sodium bicarbonate have the molecular formulaNaHCO3Is an inorganic salt. Purchased from the market.
The L-carnitine, also called L-carnitine and vitamin BT, has a chemical formula of C7H15NO3Purchased from the market.
The monosodium glutamate is sodium glutamate, is a delicate flavor seasoning, and is easily soluble in water; purchased from the market.
Compared with the prior art, the invention has the following advantages and positive effects:
1. the spray is an external medicine, adverse reactions and toxic and side effects are remarkably reduced, the permeability of the spray is good, and after the spray is quickly kneaded and absorbed by hands, the tophus can be immediately decomposed to promote blood circulation, so that pains are quickly relieved, the treatment effect is obvious, the medication compliance of patients with gouty arthritis is remarkably improved, and the life quality of the patients is improved;
2. the invention has scientific compatibility, has the advantages of quick response, short treatment course, low cost and the like, and has simple and convenient preparation process, stable and safe drug effect, stable preparation system, long-term storage, convenient use and easy popularization and application.
Detailed Description
The present invention is further described in the following description of the specific embodiments, which is not intended to limit the invention, but various modifications and improvements can be made by those skilled in the art according to the basic idea of the invention, within the scope of the invention, as long as they do not depart from the basic idea of the invention.
Preparing a eucommia bark water extract: pulverizing cortex Eucommiae, sieving with 60 mesh sieve, weighing 40g powder, boiling in 1000mL sterile distilled water for 4h, filtering with 300 mesh sieve, collecting filtrate, concentrating in water bath, evaporating to obtain dry liquid, and adding distilled water to obtain cortex Eucommiae water extract with concentration of 3 g/L.
Preparation of green olive juice: putting the cleaned green olive into boiling water, adding 0.1% citric acid solution, scalding for 5min, taking out, washing in flowing water to remove surface wax, softening pulp tissue, and protecting color; extracting the pitted olive pulp in a material-water ratio of 1:5(g/mL) for 2h at 50 ℃ and 400r/min in a temperature-controlled stirrer; filtering the extracted olive juice with gauze to obtain clear and transparent green olive juice.
The baking soda and the sodium bicarbonate have the molecular formula of NaHCO3Is an inorganic salt. Purchased from the market.
The L-carnitine disclosed by the invention is also called L-carnitine and vitamin BT, has a chemical formula of C7H15NO3, and is purchased from the market.
The monosodium glutamate is sodium glutamate, is a delicate flavor seasoning, and is easily soluble in water; purchased from the market.
Example 1
Step 1, adding 0.2g of baking soda into 99ml of alkaline ionized water, and uniformly stirring until the pH value reaches 12.5;
step 2, adding 0.1g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.1g of eucommia bark water extract and 0.01g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.01g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Example 2
Step 1, adding 1.8 of baking soda into 97g of alkaline ionized water, and uniformly stirring until the pH value reaches 13;
step 2, adding 0.5g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.5g of eucommia bark water extract and 0.1g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.1g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Example 3
Step 1, adding 1.0g of baking soda into 98g of alkaline ionized water, and uniformly stirring until the pH value reaches 12-13;
step 2, adding 0.2g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.4g of eucommia bark water extract and 0.04g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.06g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Comparative example 1:
step 1, adding 1.0g of baking soda into 98g of deionized water, and uniformly stirring;
step 2, adding 0.2g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.04g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.06g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray. .
Comparative example 2
Step 1, adding 1.0g of baking soda into 98g of alkaline ionized water, and uniformly stirring until the pH value reaches 12-13;
step 2, adding 0.4g of eucommia bark water extract into the solution obtained in the step 1, and filtering;
step 3, heating the filtrate obtained in the step 2, adding 0.06g of monosodium glutamate, standing and filtering;
and 4, concentrating the liquid obtained in the step 3 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
The first experimental example: acute footpad swelling test of sodium urate crystal of spray rat
Preparing sodium urate crystal and sodium urate solution: adding 2g of uric acid into 400ml of boiling water, adjusting the pH value to 7.4 by using NaOH (1N), heating to 95 ℃, cooling at room temperature, stirring lightly, standing at 4 ℃ for 4-6 hours, separating out flocculent precipitate, filtering to obtain microcrystalline sodium urate, and sterilizing at 80 ℃. 1000mg of sodium urate is weighed before use, fully ground and added with 20ml of sterile physiological saline to prepare 50g/L (5%) of suspension.
Grouping and administration: rats were fed adaptively for 3 days, and were randomly divided into 5 groups by weight: model control group, positive drug indomethacin group (0.0045g/kg), experiment 1 group, experiment 2 group, and experiment 3 group. The indometacin group as the positive drug is administered by intragastric administration (10ml/kg) 1 hour before causing inflammation; the other groups were coated immediately after molding (0.1L/piece), and were re-coated 6, 12, and 24 hours after inflammation, and the model groups were coated with the same volume of vehicle.
Experiment 1 group sprays prepared in example 1 of the present invention.
Experiment 2 group sprays prepared in example 2 of the present invention.
Experiment 3 group sprays prepared in example 3 of the present invention.
Comparative example 1 group.
Comparative example 2 group.
Preparing a model: the circumference of the joint was measured as a normal value by a plantar volume measuring instrument. In each group, 0.2mL of 5% sodium urate suspension was injected into the dorsal aspect of the right ankle joint (joint extension, 45 degree needle insertion) of the rats for joint cavity molding.
Swelling degree of joints: the volume of the right ankle joint was measured 6, 12, 24, 48 hours after the onset of inflammation. And the swelling degree of the joint was calculated, and the results are shown in table 1.
Swelling degree is equal to the volume of the joint after molding-the volume of the joint before molding
Table 1 effect on sodium urate induced ankle swelling in rats (X ± SD, n ═ 9)
Figure BDA0003451478910000071
Figure BDA0003451478910000081
And (4) conclusion: modeling comparison group: after 6h, the ankle joint volume of the rat is obviously increased, swelling is gradually reduced along with the time, but the ankle joint does not return to normal after 48h, and the difference is significant compared with that before inflammation (P is less than 0.01). Compared with the model group, the experiment 1 group, the experiment 2 group and the experiment 3 group obviously reduce the ankle joint volume of the rat (P is less than 0.05 and P is less than 0.01); while the comparative example 1 and comparative example 2 did not improve ankle joint volume, and were not statistically significant compared to the model control group.
Experimental example II analgesic test of spray of the present invention
A hot plate method is adopted, a mouse with the weight of 20-24 g and a female are taken, a physio-physiological experiment multi-purpose instrument is used, the temperature is adjusted to be 55 +/-0.5 ℃, and the foot of the mouse licked is used as an index of pain. The pain threshold was determined once every 5min for 2 times before administration and the mean was taken. Selecting mice with pain threshold value of 10-30 seconds, stable reaction and no jumping for test, wherein each group comprises 10 mice and is randomly divided into the following groups:
matrix group, 70% ethanol solution is given;
experiment 1 group sprays prepared in example 1 of the present invention;
experiment 2 group spray prepared in example 2 of the present invention;
experiment 3 group sprays made in example 3 of the present invention.
Comparative example 1 group.
Comparative example 2 group.
Each group of the double-sided hind paw primers was 15. mu.l/body, 15 min/time X3 times. The pain threshold is re-measured 15min, 30 min and 60 min after the last application, and is measured twice at 5min intervals, and the average is taken as the pain threshold. The results are shown in Table 2.
TABLE 2 Effect of sprays of the invention on Hot plate pain threshold in mice
Figure BDA0003451478910000082
Figure BDA0003451478910000091
The results prove that: the local spraying agent can improve the pain threshold caused by mouse hot plate method; while the sprays of the comparative examples did not increase the pain threshold in mice, it is sufficient to show that the composition of the invention is not a simple combination but an organic combination in its entirety.

Claims (4)

1. A cold compress spray for relieving gout is characterized in that the spray comprises the following raw materials: alkaline ionized water, sodium bicarbonate, L-carnitine, eucommia bark water extract, green olive juice and monosodium glutamate.
2. The cold compress spray for relieving gout as claimed in claim 1, which is characterized by comprising the following components in parts by weight:
Figure FDA0003451478900000011
3. the cold compress spray for relieving gout as claimed in claim 1, wherein the pH value of the alkaline ionized water is 10.0-10.9.
4. The cold compress spray for relieving gout as claimed in claim 1, wherein the preparation method of the spray comprises the following steps:
step 1, adding baking soda into alkaline ionized water, and after uniformly stirring, enabling the pH value to reach 12-13;
step 2, adding L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding the eucommia bark water extract and the green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
CN202111664767.0A 2021-12-31 2021-12-31 Cold compress spray for relieving gout and preparation method thereof Pending CN114224935A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111664767.0A CN114224935A (en) 2021-12-31 2021-12-31 Cold compress spray for relieving gout and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111664767.0A CN114224935A (en) 2021-12-31 2021-12-31 Cold compress spray for relieving gout and preparation method thereof

Publications (1)

Publication Number Publication Date
CN114224935A true CN114224935A (en) 2022-03-25

Family

ID=80745193

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111664767.0A Pending CN114224935A (en) 2021-12-31 2021-12-31 Cold compress spray for relieving gout and preparation method thereof

Country Status (1)

Country Link
CN (1) CN114224935A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104825554A (en) * 2015-04-22 2015-08-12 广州暨南生物医药研究开发基地有限公司 Gouty arthritis treatment spraying agent
CN109700901A (en) * 2019-01-16 2019-05-03 曲沃李时珍医药科技有限公司 A kind of Medical-use cold compress gel and its preparation method and application improving gout

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104825554A (en) * 2015-04-22 2015-08-12 广州暨南生物医药研究开发基地有限公司 Gouty arthritis treatment spraying agent
CN109700901A (en) * 2019-01-16 2019-05-03 曲沃李时珍医药科技有限公司 A kind of Medical-use cold compress gel and its preparation method and application improving gout

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
余瀛鳌等: "杜仲茶", 《这本书能让你摆脱痛风 长效降尿酸,除痛防复发》 *
余瀛鳌等: "杜仲茶", 《这本书能让你摆脱痛风 长效降尿酸,除痛防复发》, 28 February 2019 (2019-02-28), pages 138 *
佚名: "橄榄油+小苏打,外用缓解痛风", 《百度》 *
佚名: "橄榄油+小苏打,外用缓解痛风", 《百度》, 2 April 2021 (2021-04-02) *
张玎减肥: "生酮饮食如何降低尿酸?", 《百度》 *
张玎减肥: "生酮饮食如何降低尿酸?", 《百度》, 18 December 2018 (2018-12-18), pages 3 *
洪良: "连翘治失眠 樟脑酒消肿止痛 青橄榄治痛风", 《百度》 *
洪良: "连翘治失眠 樟脑酒消肿止痛 青橄榄治痛风", 《百度》, 28 September 2018 (2018-09-28), pages 1 *
灰辟教概: "痛风可以吃鸡精和味精吗 痛风可以吃生抽吗", 《百度》 *
灰辟教概: "痛风可以吃鸡精和味精吗 痛风可以吃生抽吗", 《百度》, 19 September 2018 (2018-09-19), pages 1 *
藤田纮一郎: "《水的神奇疗效》", 31 May 2007, pages: 84 *
赵春华: "中西医结合治疗痛风性关节炎13例", 《四川中医》, vol. 21, no. 09, 15 September 2003 (2003-09-15), pages 29 - 30 *
陈大舜等: "《最好的中医名著公开课 名师解读历代名医临床必读医论》", 湖南科学技术出版社, pages: 367 - 368 *

Similar Documents

Publication Publication Date Title
JPS5843996A (en) Stable s-adenosylmethionine salts, manufacture and therapeutical composition containing them as active components
CN103961556A (en) Dendrobium officinale oculentum for relieving asthenopia
CN104382005A (en) Glucosamine chondroitin collagen tablet and preparation method thereof
WO2021062888A1 (en) Complex composition with function of promoting bone and joint health and application thereof
CN114224935A (en) Cold compress spray for relieving gout and preparation method thereof
CN100350921C (en) Dermatosis eliminating medicine
CN109464512A (en) It is a kind of for treating the external wash liquid and preparation method thereof of pig scabies
CN102335462A (en) Nano iodine-chitosan cervical disease treating membrane agent and preparation method of membrane
CN1057934C (en) Electuary benefitting for liver and preparation method thereof
CN102670881A (en) Chinese medicinal composition for treating fracture and preparation method
CN107114775B (en) Blood fat reducing compound based on swim bladder polypeptide of miichthys miiuy and preparation method thereof
CN102579558B (en) Application of bauhinia championii total flavonoids in preparation of medicine for treating rheumatoid arthritis
CN100471507C (en) Traditional Chinese medicine prepn. for treating osteoporosis
CN115414368B (en) Pharmaceutical composition for treating traumatic injury and application thereof
CN1170562C (en) Medicine for treating tinea
CN114053340B (en) A Chinese medicinal composition for treating rheumatism, and its preparation method
CN107811907A (en) A kind of body lotion for promoting subcutaneous fat to decompose
CN115054645B (en) Traditional Chinese medicine composition for relieving eye fatigue and preparation method thereof
CN102697964B (en) Medicine for treating male sexual dysfunction
CN108434299B (en) Pharmaceutical composition for treating scapulohumeral periarthritis and preparation method and spray thereof
CN112999340A (en) Nasal cavity flushing fluid and preparation method thereof
CN105640792B (en) Dihydromyricetin is in beauty except the application in spot product
CN105412395A (en) Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof
CN112915185A (en) Pharmaceutical composition and preparation method and application thereof
CN1143684C (en) Medicine for treating hypertension and heart disease and its preparation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220325

WD01 Invention patent application deemed withdrawn after publication